全文获取类型
收费全文 | 7161篇 |
免费 | 900篇 |
国内免费 | 244篇 |
专业分类
耳鼻咽喉 | 85篇 |
儿科学 | 254篇 |
妇产科学 | 39篇 |
基础医学 | 2185篇 |
口腔科学 | 28篇 |
临床医学 | 672篇 |
内科学 | 850篇 |
皮肤病学 | 170篇 |
神经病学 | 99篇 |
特种医学 | 59篇 |
外国民族医学 | 3篇 |
外科学 | 399篇 |
综合类 | 545篇 |
预防医学 | 124篇 |
眼科学 | 26篇 |
药学 | 590篇 |
1篇 | |
中国医学 | 23篇 |
肿瘤学 | 2153篇 |
出版年
2024年 | 12篇 |
2023年 | 268篇 |
2022年 | 249篇 |
2021年 | 523篇 |
2020年 | 512篇 |
2019年 | 421篇 |
2018年 | 414篇 |
2017年 | 373篇 |
2016年 | 333篇 |
2015年 | 291篇 |
2014年 | 343篇 |
2013年 | 871篇 |
2012年 | 278篇 |
2011年 | 336篇 |
2010年 | 251篇 |
2009年 | 234篇 |
2008年 | 243篇 |
2007年 | 228篇 |
2006年 | 240篇 |
2005年 | 192篇 |
2004年 | 214篇 |
2003年 | 173篇 |
2002年 | 155篇 |
2001年 | 164篇 |
2000年 | 113篇 |
1999年 | 102篇 |
1998年 | 81篇 |
1997年 | 81篇 |
1996年 | 84篇 |
1995年 | 73篇 |
1994年 | 62篇 |
1993年 | 49篇 |
1992年 | 35篇 |
1991年 | 39篇 |
1990年 | 34篇 |
1989年 | 25篇 |
1988年 | 28篇 |
1987年 | 16篇 |
1986年 | 20篇 |
1985年 | 22篇 |
1984年 | 29篇 |
1983年 | 13篇 |
1982年 | 15篇 |
1981年 | 15篇 |
1980年 | 12篇 |
1979年 | 10篇 |
1978年 | 8篇 |
1977年 | 11篇 |
1976年 | 8篇 |
1972年 | 1篇 |
排序方式: 共有8305条查询结果,搜索用时 15 毫秒
1.
2.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):327-334.e2
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone. 相似文献
3.
4.
5.
Patrick Demkowicz BS Renelle Pointdujour-Lim MD Sofia Miguez BA Yesung Lee BS Bailey S. C. L. Jones BS Christopher A. Barker MD Marcus Bosenberg MD PhD David H. Abramson MD Alexander N. Shoushtari MD Harriet Kluger MD Jasmine H. Francis MD Mario Sznol MD Mathieu F. Bakhoum MD PhD 《Cancer》2023,129(20):3275-3286
6.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
7.
8.
This commentary reviews top advances in hepatobiliary cancer research in 2021–2022, focusing on leveraging immunotherapeutics in combination with other therapies earlier in the disease course and targeted to patient's individualized biomarkers that may predict response or resistance to checkpoint inhibitors. 相似文献
9.
10.
Darren Ming‐Chun Poon 《Asia-Pacific Journal of Clinical Oncology》2020,16(Z3):18-23
For advanced and metastatic urothelial carcinomas (UCs), platinum (preferably cisplatin)‐based chemotherapy has been the standard treatment for many years. However, many patients are ineligible for cisplatin‐based chemotherapy because of poor performance status and/or other age‐related conditions. At the other end of the spectrum, patients with localized non‐muscle–invasive bladder cancer who are unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) treatment often face radical cystectomy as the only option. In recent years, the application of immunotherapy in the form of immune‐checkpoint inhibitors has provided viable alternatives in the second‐line postplatinum and first‐line cisplatin‐ineligible settings. Recent and ongoing clinical trials are also assessing the safety and efficacy of immunotherapy for neoadjuvant and adjuvant uses before/after cystectomy, for BCG‐unresponsive cases, and for combination treatments that include the newer indoleamine 2,3‐dioxygenase‐1 inhibitors and/or BCG. This review summarizes recent developments in immunotherapy for UCs. 相似文献